ALL orders are active unless: 1. Order is manually lined through to inactivate 2. Orders with check boxes ( ) are unchecked

**DRUG AND TREATMENT ORDERS**

**SUB Hemostasis with Femostop Device**

This plan is designed to be used as part of a larger plan not independently. Please do NOT order individually*(NOTE)*

**Vital Signs**
- Vital Signs
  - Q15MINS x 2, then Q30MINS x 2, Q1H x 4, then Routine. If patient is admitted, progress to routine vital signs per unit policy, after recover vital signs. Assess neuro/circulation status of affected extremity with each pulse check
- Neurovascular Check Monitoring
  - Q15MINS x 2, Assess for bleeding and document pulses distal to cath site with each vital sign
- **+30 Minutes** Neurovascular Check Monitoring
  - Q30MINS x 2, Assess for bleeding and document pulses distal to cath site with each vital sign
- **+90 Minutes** Neurovascular Check Monitoring
  - Q1H x 4, Assess for bleeding and document pulses distal to cath site with each vital sign
- Neurovascular Checks
  - Q15MINS x 4, Assess for bleeding and document pulses distal to cath site
- **+1 Hours** Neurovascular Checks
  - Q30MINS x 4, Assess for bleeding and document pulses distal to cath site
- **+2 Hours** Neurovascular Checks
  - Q1H x 4, Assess for bleeding and document pulses distal to cath site

**Activity**
- Reverse Trendelenburg PRN Order, May place in reverse trendelenberg as needed.
- Elevate Head of Bed
  - 30 Degrees, 4, hour, 30-40 degrees; post sheath removal

For the Bedrest Activity orders, the Duration and Duration unit order details must be satisfied after calculating the appropriate duration based on procedure end time.(NOTE)*

**Activity**
- Bedrest, 8, hour, May log roll to operative leg side with nurse’s assistance and NO BENDING of operative leg *(DEF)*
- Bedrest, 6, hour, Post Sheath Removal. With operative leg straight (NO BENDING). May log roll to operative leg side with nurse’s assistance and NO BENDING of operative leg.

**PHYSICIAN SIGNATURE ___________________________ DATE __________ TIME ________**

**DRUG ALLERGIES**

<table>
<thead>
<tr>
<th>WT:</th>
<th>KG</th>
</tr>
</thead>
</table>

A pharmaceutical equivalent or pharmaceutical alternative may be substituted. Therapeutic alternatives may be substituted as determined by the Pharmacy and Therapeutics Committee.

**ORDERS**

REV: 2/2012

Page 1 of 2
For the Dangle and Ambulate in Room Activity orders, the Offset Details must be satisfied after calculating the appropriate start time based on expiration of Bedrest order (NOTE)*

- **Activity**
  - Bedrest, until AM then Dangle in AM
- **Activity**
  - Dangle at Bedside, 6, hour, Post hemostasis/femostop removal. Dangle feet at bedside. If no complications with procedural site while dangling, may progress with ambulation and bathroom privileges as tolerated.
- **+8 Hours** Activity
  - Ambulate in Room, With BRP

**Nursing Orders**

- **Communication Order**
  - Nursing to draw Istat ACT, ONCE, If patient received Heparin, obtain ACT one hour post bolus. Remove sheath when LESS than 160 seconds. If GREATER than 160 seconds, repeat Q1H until LESS than 160 seconds
- **Apply Femostop**
  - ONCE, Pressure Setting: 0-20 mmHg, Special Instructions: If Femostop pressure is at 20 mmHg, release femostop pressure for 5 minutes every hour; Document femostop pressure with each pulse check.
- **Communication Order**
  - When hemostasis achieved, continue to apply low pressure at 0-20 mmHg for 4 hours. Maximum of 12 hours
- **Communication Order**
  - Check site for hematoma and document pedal pulses and vital signs every 15 minutes x 4, every 30 minutes x 2, then hourly while femostop in place
- **Communication Order**
  - When femostop discontinued, check and document site and distal pulses every 30 minutes x 2, every hour x 2, then with each routine vital sign.
- **Wound Care**
  - DAILY, Clean site with Cloraprep and apply adhesive bandage
- **Dressing Removal**
  - Remove tegaderm dressing in AM post procedure

A pharmaceutical equivalent or pharmaceutical alternative may be substituted. Therapeutic alternatives may be substituted as determined by the Pharmacy and Therapeutics Committee.